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1389Metabolic Impairment in Heart Failure
The Myocardial and Systemic PerspectiveABSTRACTAlthough bioenergetic starvation is not a new concept in heart failure (HF), recent research has led to a growing
appreciation of the complexity of metabolic aspects of HF pathophysiology. All steps of energy extraction, transfer,
and utilization are affected, and structural metabolism is impaired, leading to compromised functional integrity of
tissues. Not only the myocardium, but also peripheral tissues and organs are affected by metabolic failure, resulting
in a global imbalance between catabolic and anabolic signals, leading to tissue wasting and, ultimately, to cachexia.
Metabolic feedback signals from muscle and fat actively contribute to further myocardial strain, promoting disease
progression. The prolonged survival of patients with stable, compensated HF will increasingly bring chronic
metabolic complications of HF to the fore and gradually shift its clinical presentation. This paper reviews recent
evidence on myocardial and systemic metabolic impairment in HF and summarizes current and emerging therapeutic
concepts with speciﬁc metabolic targets. (J Am Coll Cardiol 2014;64:1388–400) © 2014 by the American College of
Cardiology Foundation.D espite therapeutic advances in heart failure(HF) therapy, the disease remains a majorchallenge. Between 1979 and 2004, the
number of HF hospitalizations in the United States
tripled, with more than 80% of cases among patients
age 65 years or older (1). The neuroendocrine activa-
tion paradigm is the cornerstone of current patho-
physiological understanding of HF, and most
current medical therapies that impact survival block
neuroendocrine activation (Central Illustration). How-
ever, evidence is mounting that this does not fully
explain the complexity of HF pathophysiology. Addi-
tional mechanisms, such as inﬂammatory activation
and metabolic impairment, are increasingly the focus
of research for novel therapeutic concepts.
Metabolic failure as an important underlying
mechanism is neither a new nor an exclusive concept
for HF, but is a typical adaptive biological response to
injury. In HF, the metabolic perspective is usually
attributed to the myocardium. (See the Online
Appendix for an overview of current concepts of
myocardial metabolic and energetic failure.)
Beyond myocardial metabolic failure, systemic
(peripheral) metabolic regulation is increasingly
recognized as contributing both to major symptoms
(muscle weakness, fatigue, exercise limitation, and
dyspnea) and to disease progression. Along with
prolonged patient survival in a stable, recompensated
state, new clinical features and comorbidities of long-
term disease progression, such as the development of
insulin resistance, anemia, hyperuricemia, and car-
diac cachexia, are coming to the fore. The growing
complexity of HF pathophysiology will increase theneed for treatment strategies tailored to speciﬁc
characteristics of patient subgroups.
This review focuses on current bioenergetic con-
cepts in HF, with particular emphasis on involvement
of peripheral tissues and organs in the complex
imbalance of energy metabolism and hormonal and
inﬂammatory regulation and on current and emerging
therapeutic concepts. Targeting the metabolic aspect
of HFwith novel, speciﬁc interventionsmay emerge as
a new frontier in HF therapy, complementary to the
neuroendocrine paradigm.
PERIPHERAL METABOLISM IN HF
Because of increased recognition of the metabolic
perspective, HF is currently appreciated as a sys-
temic and multiorgan syndrome (Central Illustration).
Activated feedback signals from peripheral reﬂex
circuits (2), systemic dysregulation of several hor-
monal pathways (3), and global metabolic imbalance
(4) are intrinsic features of HF pathophysiology.
Systemic metabolic concepts have pathophysiologic
and therapeutic implications. Signals, such as
inﬂammation, insulin resistance, anabolic blunting,
and oxygen radical accumulation, not only affect the
myocardium, but exert detrimental effects on a
systemic level. These peripheral metabolic derange-
ments contribute to the major symptoms and disease
progression of HF. Moreover, speciﬁc metabolic
therapeutic concepts to improve substrate utilization
and energetic efﬁciency will affect both myocardial
and peripheral tissues, namely skeletal muscle
(Figure 1).
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1390Although skeletal muscle is the obvious
target of metabolic failure and subsequent
decline in functional capacity, other tissue
compartments, such as fat and bone, are
similarly involved. The interaction of meta-
bolic signals between these tissues, global
effects on body composition changes, and
the development of sarcopenia and cachexia
will be discussed.
ANABOLIC FAILURE. Metabolic derange-
ments in congestive heart failure (CHF) can
be described globally as an overall catabolic/
anabolic imbalance (5), with blunted anabolic
capacity and catabolic dominance. Anabolic
blunting includes a range of signals (6).INSULIN RESISTANCE. Detailed information on in-
sulin resistance can be found in the Online Appendix.
Beyond its glucoregulatory effect, insulin is 1 of
the strongest anabolic stimulatory signals, acting
via repression of catabolic genes and activation of
transcription factor 4 (also called CREB2), and isRAL ILLUSTRATION Evolving Paradigm of HF Pathophysiolo
cing complexity of heart failure (HF) pathophysiology from a mer
ormonal, immune, and metabolic pathways. Current therapeutic co
ion (left column). Novel therapies are warranted to target crucia
matory activation. ACE ¼ angiotensin-converting enzyme; AT Rec
¼ hydralazine and isosorbide dinitrate; ICD ¼ implantable cardi
mineralocorticoid receptor; TNF ¼ tumor necrosis factor; Tx ¼ thcomplementary to the general amino acid control
pathway (7). The normal anabolic response to insulin
and amino acid stimulation was reduced in HF pa-
tients by more than 50% because of both a blunted
protein anabolic response (8) and increased proteoly-
sis (9). Even in nondiabetic patients, insulin resistance
in HF progresses in parallel to HF severity and predicts
impaired functional capacity of cardiovascular and,
particularly, of muscle function (10). Beyond mor-
bidity, insulin resistance is a prognostic factor pre-
dicting reduced survival independent of other
established prognostic markers (11) and may be
regarded as a principal metabolic feature of HF path-
ophysiology. Multiple signals in a complex interplay
of mechanisms contribute to insulin resistance in
HF, including neurohormonal activation (catechol-
amines), inﬂammatory cytokines (tumor necrosis fac-
tor [TNF]-alpha), oxidative stress (reactive oxygen
species [ROS]), and hemodynamic impairment (tissue
hypoperfusion) (Figure 2, right) (12,13). Impaired in-
sulin signaling may, in turn, drive HF progression via
multiple mechanisms, such as impaired metabolicgy
e hemodynamic disorder to an increasingly systemic involvement of
ncepts focus exclusively on hemodynamic failure and neuroendocrine
l components of HF pathophysiology, such as metabolic failure and
¼ angiotensin receptor; CRT ¼ cardiac resynchronization therapy;
overter-deﬁbrillator; LVAD ¼ left ventricular assist device;
erapy; XO ¼ xanthine oxidase.
FIGURE 1 Myocardial Energy Metabolism
Cellular energy metabolism from substrate utilization to oxidative phosphorylation to energy transfer for energy-requiring processes. Current
therapeutic concepts to improve energetic efﬁciency (purple arrows) predominantly target proportional substrate use by decreasing fatty acid
metabolismand increasingglucoseoxidation. ADP¼ adenosinediphosphate; ATP¼ adenosine triphosphate; CPT¼ carnitine palmitoyltransferase;
Cr¼ free creatine; FA¼ fatty acid; FFA¼ free fatty acids; G6P¼ glucose-6-phosphate; GLUT4¼ glucose transporter 4; HK¼ hexokinase; LPL¼
lipoproteinlipase; MCD¼malonyl-CoA decarboxylase; PCr ¼ phosphocreatine; PDH¼ pyruvate dehydrogenase; ROS ¼ reactive oxygen species;
TCA ¼ tricarboxylic acid cycle (Krebs cycle); TG ¼ triglycerides; UCP ¼ uncoupling protein; ß-ox ¼ beta oxidation.
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(Figure 2, left).
GROWTH HORMONE RESISTANCE. The growth hor-
mone (GH)–insulin-like growth factor-1 (IGF-1) axis is
a key regulatory pathway of anabolic signaling, with
Akt/mTOR as downstream mediators. An acquired
GH-resistant state has been described in HF, with a
typical pattern of high GH levels and low IGF-1 levels
(14). GH levels were increased 3-fold in CHF patients
with signiﬁcant weight loss (i.e., cachexia) compared
with noncachectic patients and healthy subjects. In
contrast, IGF-1 levels are reduced, particularly in pa-
tients with cachexia (15). Acquired GH resistance may
explain the disappointing results of several studiesthat tested the GH administration as a therapeutic
approach in patients with CHF (16).
ANABOLIC STEROID METABOLISM. Anabolic de-
ﬁciencies, such as low dehydroepiandrosterone sul-
fate, testosterone, or IGF-1 levels are common ﬁndings
in HF (6). In HF patients, this steroid metabolism
impairment translates into impaired exercise capacity
and symptomatic status (17). Each anabolic hormone
deﬁcit independently predicts poor prognosis, with
additive effects if more than 1 is decreased (6).
A range of hormones involved in metabolic control,
such as ghrelin (18), leptin (13), resistin (19), adipo-
nectin (20), and natriuretic peptides (21), are imbal-
anced in CHF. Additional factors, beyond the scope of
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bolic balance. The central regulation of appetite with
mutual interaction of the lateral (feeding area) and
medial (satiety area) hippocampal nuclei is under the
control of amultitude ofmediators (e.g., neuropeptide
Y, leptin, orexin, inﬂammatory cytokines, and others),
and their abnormal regulation impacts feeding
behavior. Indeed, reduced appetite is common in HF
patients (4). Furthermore, gastrointestinal absorption
is impaired in CHF, adding to the imbalance between
nutritional supply and energy demands (22).TISSUE WASTING IN CHF
The overall net catabolic dominance (outlined in
the preceding text) accounts for systemic tissue
wasting. Skeletal muscle wasting may be the most
clinically relevant aspect, as it determines physical
capacity and symptomatic severity of HF. However,
fat and bone tissue are also affected by global cata-
bolic dominance. As a consequence of global tissue
wasting, weight loss, the hallmark of cardiac cachexia
(see later discussion), may occur in the course of HFFIGURE 2 Insulin Resistance: Intrinsic Feature in HF Pathophysiolog
The vicious cycle of insulin resistance as an intrinsic component of heart
resistance (right section in red). In turn, insulin resistance induces a range o
is a major underlying mechanism of the reciprocal interaction between co
additive effects in overt DM. AGE ¼ advanced glycation end products; PA
sympathetic nervous system; TNF ¼ tumor necrosis factor; other abbrevias a clinical manifestation of catabolic dominance and
an indicator of progressing disease.
SKELETAL MUSCLE. Skeletal muscle is the main
effector organ for physical activity and the body’s
largest amino acid storage pool. Accordingly, 2 major
issues for skeletal muscle metabolism in HF need to be
addressed: 1) impaired energy metabolism affecting
contractile function; and 2) structural metabolism to
balance the body’s protein pool. Indeed, a generalized
metabolic myopathy, characterized by decreased
oxidative capacity, impaired substrate use and energy
transfer, and an overall catabolic/anabolic imbalance,
has been suggested for HF (5,23).
Peroxisome proliferator-activated receptors alpha,
beta, and gamma are central players in the regulation
of energy metabolism in heart and skeletal muscle
(24). Impaired regulation via the inducible coactivator,
PCGC-1 alpha, has been linked to reduced muscle
oxidative capacity. Increased proinﬂammatory cyto-
kine levels (particularly TNF-alpha, interleukin [IL]-6,
and IL-1ß), both in the circulation and locally in skel-
etal muscle tissue, have been described in HF (25).
These cytokines trigger multiple signaling cascadesy
failure (HF) pathophysiology. Several features of HF trigger insulin
f signals responsible for HF progression. Accordingly, insulin resistance
ngestive HF and diabetes mellitus, with hyperglycemia only exerting
RP ¼ poly(ADP-ribose) polymerase; PKC ¼ protein kinase C; SNS ¼
ations as in Figure 1.
FIGURE 3 Independent Lipolysis Pathways in CHF
Independent signaling pathways of increased lipolytic activity in heart failure. All 3
pathways are activated in congestive heart failure (CHF). ANP ¼ A-type natriuretic peptide;
AR ¼ adrenergic receptor; BNP ¼B-type natriuretic peptide; cAMP ¼ cyclic adenosine
monophosphate; cGMP ¼ cyclic guanosine monophosphate; c-Jun = N-terminal kinases;
CNP = C-type natriuretic peptide; FFA = free fatty acids; JNK ¼ c-Jun N-terminal kinase;
MAPK ¼ mitogen activated protein kinase; NP rec ¼ natriuretic peptide receptor; PKA ¼
protein kinase A; PKG ¼ protein kinase G; TG ¼ triglyceride; TNF ¼ tumor necrosis factor.
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ROS accumulation, impaired contractile capacity,
decreased energetic efﬁciency via increased uncou-
pling protein activation, insulin resistance, growth
suppression, and catabolic activation (26).
Myostatin, a cytokine of the transforming growth
factor (TGF)-beta family has garnered increasing
attention as a potent muscle growth regulator. It is
most abundantly expressed in skeletal muscle, with
lower, but inducible, expression in the heart and in
adipose tissue (27). A systemic effect of myostatin
spillover from the myocardium in HF patients may
contribute to ﬁber type-shifting (28), insulin resis-
tance, and skeletal muscle wasting (29).
The skeletal muscle protein pool undergoes con-
stant synthesis and degradation with a highly regu-
lated and balanced turnover rate. In HF, a global
imbalance accounts for muscle wasting (i.e., sarco-
penia) or, ultimately, development of cachexia (see
later discussion). Up to 68% of CHF patients show
signs of muscle atrophy (30). This process starts early
in the course of the disease, even before weight loss
can be detected, when replacement of muscle tissue
by nonfunctional tissue may occur. These skeletal
muscle metabolic abnormalities may be more rele-
vant to explaining major HF symptoms such as fa-
tigue, exercise limitation, and dyspnea than central
hemodynamic parameters (31).
FAT TISSUE. Identiﬁcation of the lipocyte hormone
leptin was the ﬁrst to establish the endocrine activity
of fat tissue. Adipose tissue is actively involved in
metabolic regulation in HF. Multiple signals and me-
diators from adipose tissue participate in local and
systemic metabolic crosstalk affecting feeding, en-
ergy expenditure, insulin resistance, and body
composition (32) (Online Appendix).
Catabolic activation is particularly apparent
in adipose tissue, as several independent path-
ways exert lipolytic signals on hormone-sensitive
lipase (Figure 3). First, catecholamines, via beta-
adrenoceptors, are classical signals for lipolysis by
activation of adenylate cyclase and increased cyclic
adenosine monophosphate (cAMP) synthesis. In
humans, the balance between lipolytic beta-receptor
expression and inhibitory alpha2-receptor expres-
sion determines the net effect of catecholamines on
lipolysis (33). As a second complex lipolytic signal,
the cytokine TNF-alpha induces lipolysis through
mitogen activated protein kinases p44/42 and JNK via
cAMP increase and lipase activation (34). NF-kappaB
activation promotes expression of lipogenesis genes.
TNF-alpha also attenuates insulin-mediated anti-
lipolytic signals and interacts with other adipokines,
such as adiponectin and IL-1. A third independentlipolysis signaling pathway was recently described,
in which natriuretic peptides (NPs) exert lipolytic
activity, with A-type NPs having the strongest effect
(35). Importantly, hormone-sensitive lipase activa-
tion by NPs is independent of cAMP signaling.
Instead, NP receptor binding promotes a cyclic gua-
nosine monophosphate pathway to activate lipase in
parallel to (but independent of) the catecholamine-
induced cAMP-protein kinase A pathway (36).
Catecholamines, TNF-alpha, and NPs are all
increased in HF, suggesting that lipolysis is pro-
foundly and multiply activated, as has indeed been
observed (37). Moreover, lipogenetic enzymes, such
as fatty acid synthase and acetyl CoA carboxylase, are
under insulin control and, as outlined earlier, the
antilipolytic effect of insulin may be blunted in the
insulin-resistant conditions of HF (38). Adipose-
derived signals contribute to paracrine and systemic
metabolic regulation. Leptin levels, which are tightly
regulated by the amount of fat tissue, are elevated in
HF, and an association with insulin resistance has
been observed (13). However, in cachectic patients,
after adjustment for the severely reduced fat tissue
mass, a hyperleptinemic state is apparent (14). Adi-
ponectin, an adipokine with multiple metabolic ac-
tions, increases both locally and globally with HF
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(20,40). Reports on adiponectin as independent pre-
dictor of increased mortality support the signiﬁcance
of fat tissue and its metabolic interactions for HF
pathophysiology and outcome (20,39).
BONE TISSUE. Osteopenia and genuine osteoporosis
beyond normal age-related associations have been
observed in HF and advance with higher stages of the
disease (41). Patients with severe HF and those with
cachexia demonstrate pronounced loss of bone mass
(42), although no direct associations with impaired
left ventricular (LV) ejection fraction or peak VO2
were observed (43). In advanced HF, signiﬁcant bone
loss occurs frequently (in 30% of patients [44]) and as
a component of overall tissue wasting (see later
discussion).
A number of bone tissue metabolic markers are
abnormally regulated in HF, such as osteocalcin,
ß-cross Laps, osteoprotegerin, RANK, and RANKL
(see Zittermann et al. [45] for review). Increased
osteolytic activation seems to be the dominant factor,
with impaired bone formation being of secondary
relevance (46). Osteolytic stimulation in HF is likely
the result of multiple factors, including vitamin D
insufﬁciency, elevated parathyroid hormone levels
(41), renal dysfunction, reduced anabolic stimulation
(such as from IGF-1), proinﬂammatory activation,
disuse atrophy, and HF-related drug administration
such as vitamin K antagonists and loop diuretics (45).
CARDIAC CACHEXIA. As described in the previous
text, systemic catabolic/anabolic imbalance leads to
tissue wasting, weight loss, and ultimately to devel-
opment of cachexia. Although wasting has been
observed in HF since ancient times as a signum mali
ominis (47), or a sign of ill omen, increasing interest
has recently focused on clinical implications, patho-
physiologic mechanisms, and, most importantly,
therapeutic options for cardiac cachexia. Cachexia
is recognized today as a severe complication of CHF
that worsens clinical symptoms and carries a partic-
ularly grave prognosis. Mortality in HF patients with
cachexia was as high as 50% at 18 months of follow-
up, compared with 17% in noncachectic patients (48).
Factors triggering progression from clinically and
weight-stable ambulatory CHF to a metabolically
imbalanced and weight-losing state are not under-
stood. Early stages of mild weight loss may go
unrecognized by doctors and patients (49). A pre-
cachexia phase has been deﬁned to emphasize
an “at risk” state (50). Biochemical features of meta-
bolic failure (e.g., inﬂammation, impaired glucose
tolerance, anemia, hypoalbuminemia, or anorexia)
may already be apparent. A body weight loss of 6%or more (excluding edema-related weight shift)
was conﬁrmed as a strong, independent predictor
of increased mortality (51). Similarities with other
chronic illnesses suggest a common ﬁnal pathway in
the metabolic response, regardless of the origin of the
illness (52). To improve clinical awareness and early
medical intervention, a common deﬁnition of cachexia
in chronic illness was proposed, deﬁning cachexia
as weight loss of$5% in#12 months in the presence of
an underlying illness, when accompanied by 3 of 5
symptomatic and biochemical criteria (53). The seem-
ingly small amount of weight lost underscores
that even mild tissue wasting in the presence of an
illness such as HF is a signiﬁcant sign of catabolic
stimulation.
IRON DEFICIENCY BEYOND ANEMIA
Until recently, surprisingly little attention was paid to
anemia in HF, presumably because mild anemia is
very common in HF and is often regarded by clini-
cians as merely the result of hemodilution due to ﬂuid
retention. Recent studies have shown that iron deﬁ-
ciency is the most common cause of anemia in HF,
accounting for up to 73% of cases in severe HF (54).
Absolute iron deﬁcit with depletion of endoge-
nous iron stores may result from covert blood loss
and/or nutritional deﬁcit. More importantly, a func-
tional iron deﬁciency may develop in HF as a conse-
quence of latent inﬂammatory activation. In this
regularly observed situation, despite only marginally
decreased endogenous iron stores, circulatory iron
for transfer to iron-dependent tissues is reduced.
Hepcidin, the central regulator of the iron homeo-
stasis, controls both gateways for circulatory iron
balance: duodenal iron absorption from the intestine
and release from enterocytes and endogenous iron
stores in macrophages (55). Hepcidin inhibits the iron
export protein ferroportin, blocking iron export from
cells into the circulation (56). Hepcidin expression is
regulated by signals of iron balance, erythropoietic
activity, and hypoxia. Additionally, proinﬂammatory
stimuli, such as lipopolysaccharide and cytokines
IL-1 and -6, are potent inducers of hepcidin via the
JAK/STAT pathway (57), over-riding erythropoietic
signals (58). Under bacterial stress, iron would be
sequestered, thus depriving iron-dependent bacterial
metabolism. However, in HF and other chronic ill-
nesses, low-grade chronic inﬂammatory activation
may block endogenous iron stores, preventing ade-
quate iron utilization for erythropoietic and metabolic
demands. Anemia of chronic illness, the prevalent
type of anemia in HF (59), has been deﬁned on this
basis (60).
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oxygen transport capacity (i.e., low hemoglobin),
tissue iron deﬁciency also has signiﬁcant implications
for mitochondrial oxygen utilization in HF. Replen-
ishment of depleted iron stores by intravenous iron
supplementation in HF patients improved their
symptomatic status and exercise capacity (61),
regardless of the presence of anemia, and did not
depend on increasing hemoglobin levels. In accor-
dance with this study, iron deﬁciency has been shown
to exert an additive effect on impaired exercise ca-
pacity in HF patients with and without anemia (62).
At the cellular level, most of the iron is transferred to
mitochondria, where it is assigned to 3 major pro-
cessing pathways: 1) synthesis of bioactive heme; 2)
synthesis of iron-sulfur clusters; or 3) mitochondrial
iron storage (63). Whereas heme is the central pros-
thetic group of all hemoproteins, including hemo-
globin, iron-sulfur clusters are required for electron
transport ability in the mitochondrial respiratory
chain and for many other enzymatic electron transfer
activities in the mitochondrion, cytosol, and nucleus.
Mitochondrial iron storage is controlled by mito-
chondrial ferritin, which sequesters iron in order to
prevent uncontrolled oxidative reactions (64).
HYPERURICEMIA
Hyperuricemia is commonly present in CHF and is
strongly associated with disease severity (65) and
mortality (66). Accordingly, uric acid (UA) has been
included as a metabolic marker and an independent
factor in the Seattle Heart Failure Survival Score (67).
The debate is ongoing as to whether UA has a func-
tional role in HF pathophysiology or is merely a dis-
ease progression marker. Currently, up-regulated
xanthine oxidase (XO) enzymatic activity is seen as
the key pathophysiologic feature of hyperuricemia. It
results from a number of factors, including increased
tissue turnover, tissue hypoxia (68), catabolism (65),
insulin resistance (69), and cell death. Accelerated
purine degradation and direct XO stimulation by
inﬂammatory cytokines and oxygen radicals (70)
account for XO’s up-regulated activity. With the
degradation of xanthin and hypoxanthin to UA, XO
produces stoichiometric quantities of free oxygen
radicals (ROS), and is a major source of ROS. XO-
derived ROS accounts for a range of detrimental
effects on endothelial function, contractility, inﬂam-
matory activation, mitochondrial damage, and
decreased metabolic efﬁcacy (see Doehner and Land-
messer [71] for review). Increased XO-dependent ROS
production as an underlying pathologic mechanism
received further support from multiple interventionaltrials with and without XO inhibition. Therapeutic XO
inhibition favorably affects a range of surrogate
markers (72). In contrast, treatments using uricosuric
treatment (73) or further enzymatic UA degradation
(74) to lower UA levels without XO inhibition did not
yield similar beneﬁcial effects.
METABOLIC THERAPEUTIC INTERVENTIONS
Better understanding of the underlying mechanisms
have made metabolic and bioenergetic regulation a
promising target for novel therapy concepts. (For
principles of bioenergetic metabolism and alterations
in HF, see the Online Appendix.) A number of thera-
pies developed on the basis of pathophysiologic
concepts have been investigated, as outlined in pre-
vious sections, and early trials have reported prom-
ising results (Figure 1). Despite these advances, no
approved medical therapy speciﬁcally targeting the
metabolic facet of HF currently exists.
THERAPIES THAT ALTER SUBSTRATE UTILIZATION.
Although fatty acid oxidation theoretically requires
approximately only 10% to 12% more oxygen per
molecule of ATP generated than glucose oxidation,
in vivo studies have shown a substantial reduction in
cardiac mechanical efﬁciency of approximately 40%
to 50% (75). This is thought to be due to increased
mitochondrial uncoupling (Online Appendix) and
to fatty acids undergoing futile metabolic cycles.
Whereas glucose uptake is typically maintained or
even increased in HF, carbohydrate oxidation is
reduced due to a block at the level of the pyruvate
dehydrogenase (PDH) complex. This led to the
concept that increased PDH activity (either directly or
via reduced fatty acid oxidation) would substantially
increase the efﬁciency of energy generation in HF.
Dichloroacetate, which increases PDH activity, is
clinically used in the treatment of lactic acidosis, and
increases LV contractile work in HF patients while
reducing myocardial oxygen consumption (76).
Several drugs have been evaluated that putatively
work via inhibition of fatty acid utilization.
Reduct ion in plasma free fatty ac id levels by
inh ib i t ing ad ipose l ipoprote in l i pase ac t i v i t y .
Nicotinic acid derivatives, such as acipimox, sub-
stantially reduce plasma free fatty acids (FFAs) via
inhibition of adipose lipoproteinlipase. As assessed
by positron emission tomography, acute administra-
tion of acipimox in patients with HF reduced fatty
acid uptake and increased glucose uptake, but did not
improve LV contractility and mechanical efﬁciency
(77). The PDH block may not have been alleviated
acutely, and therefore, low carbohydrate oxidation
would remain. Moreover, acutely reduced plasma
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Longer-term (28-day) therapy in patients with sys-
tolic HF was recently tested and showed no effects on
LV systolic function (78).
Reduct ion of fatty ac id ut i l i zat ion v ia CPT1/2
inh ib i t ion . The carnitine shuttle is the rate-limiting
step in fatty acid metabolism, and therefore is an
attractive therapeutic target. Malonyl-CoA is a potent
endogenous inhibitor of CPT1. Increased malonyl-
CoA and subsequent CPT1 inhibition can be ach-
ieved by inhibiting malonyl-CoA decarboxylase, the
enzyme catalyzing malonyl-CoA degradation. This
results in reduced fatty acid utilization and increased
carbohydrate oxidation (79). There are also direct
pharmacological inhibitors of the carnitine shuttle.
Etomoxir and oxfenicine irreversibly inhibit CPT1,
whereas perhexiline reversibly inhibits CPT1 and 2 in
isolated liver and cardiac mitochondria (80). Oxfeni-
cine slowed HF development in a canine rapid pacing
HF model (81). Etomoxir improved contractile LV
dysfunction and exercise hemodynamics in experi-
mental (82) and in clinical HF (83), but a randomized
controlled trial was terminated very early because of
substantial increases in liver transaminases (84).
Perhexiline is an effective antianginal agent that
was used in the 1970s and early 1980s, but was
voluntarily withdrawn by the manufacturers because
of apparently idiosyncratic cases of liver toxicity
and peripheral neuropathy. Subsequent studies (80)
demonstrated that this toxicity resulted from phos-
pholipid accumulation in liver and peripheral nerves
due to variations in metabolic degradation via the
Cyp2D6 enzyme. The toxic accumulation is prevent-
able by monitoring plasma levels with appropriate
dose titration (85). In randomized controlled trials,
perhexiline in addition to standard therapy improved
peak oxygen consumption, LV ejection fraction, and
quality of life (Minnesota Living With Heart Failure
questionnaire score) (86) and cardiac energetic status
(phosphocreatine/ATP ratio [87]). Additional effects
of perhexiline include reduced generation of super-
oxide by NOX 2 enzymes (88), reduced expression of
thioredoxin-interacting protein (an inhibitor of thio-
redoxin and of glycolysis [89]) and inhibition of
mTOR C1 (potentially leading to improved cell sur-
vival via increased autophagy [90]).
CPT1 inhibition was also reported with the beta-
blockers carvedilol and metoprolol (91,92) and with
amiodarone (80). Sulfo-N-succinimidyl esters of long
chain fatty acids, including sulfo-N-succinimidyl
palmitate and sulfo-N-succinimidyl oleate inhibit
long chain fatty acid uptake into the cell via the
CD36 transporter. Accordingly, sulfo-N-succinimidyl
palmitate was shown to reduce palmitate uptake inisolated rat hearts, which is associated with devel-
opment of LV hypertrophy (93).
Pa r t i a l i nh i b i t i on o f f a t ty a c i d be ta ox id a t i on .
Trimetazidine and ranolazine both inhibit fatty acid
beta oxidation. Like perhexiline, trimetazidine is an
effective anti-anginal agent, reducing fatty acid up-
take and increasing glucose oxidation due to PDH
activation (94). In a positron emission tomography
study in patients with dilated cardiomyopathy, tri-
metazidine had little effect on fatty acid uptake from
the bloodstream, but appeared to reduce fatty acid
utilization from intracellular fat stores and increased
insulin sensitivity (95,96). Trimetazidine improves
cardiac energetic status (phosphocreatine/ATP ratio)
in patients with HF (97) and improves symptomatic
status, including New York Heart Association func-
tional class and exercise time, LV ejection fraction, and
hospitalization due to HF. In addition to inhibiting
lipid oxidation, recent evidence suggests that ranola-
zine’s predominant therapeutic beneﬁt may relate to
inhibition of the slow inward sodium-channel (98).
INSULIN SENSITIZERS AND GLUCOREGULATORY
AGENTS. Global insulin resistance is characteristic of
HF (see Online Appendix for principles of insulin
resistance in HF); thus, improving insulin sensitivity
is an intriguing option.
Thiazo l id ined iones . Thiazolidinediones (TZDs) are
insulin sensitizers and peroxisome proliferator-
activated receptor-gamma agonists. Despite the
theoretical advantages of insulin sensitization in HF,
TZDs cause ﬂuid retention, probably explaining the
increased HF symptoms and hospitalizations in a
study of 4,447 type 2 diabetic patients in which
rosiglitazone was compared with metformin plus a
sulfonylurea (99).
The conﬁrmed weight gain with TZD therapy is
conventionally seen as an unwanted side effect in
diabetic patients, resulting from improved anabolic
capacity and restored insulin sensitivity. However,
this anticatabolic effect is intriguing in chronic ill-
nesses with catabolic dominance, such as HF. Indeed,
a retrospective analysis of the PROactive study has
shown that glitazone-induced weight gain in diabetic
patients with cardiovascular comorbidity was associ-
ated with improved survival (100).
Metformin . Biguanides (metformin) improve insulin
sensitivity and have beneﬁcial effects on mortality
(101) and cardiopulmonary function (102). Metformin
carries an extremely small risk of inducing lactic
acidosis in HF patients (103), resulting in caution
in its use in diabetics with HF. It acts (at least in
part) via phosphorylation (activation) of adenosine
monophosphate kinase, a key energy sensor. Recent
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shown that metformin treatment in type 2 diabetic
patients with HF resulted in lower all-cause mortality
than in those treated with other agents (104).
As insulin resistance is a relevant feature of
HF pathophysiology, antidiabetic treatments aiming
merely at higher endogenous or administered insulin
levels may seem less suitable for metabolic in-
terventions in HF.
INCRETIN-BASED THERAPIES. Glucagon-like pep-
tide (GLP)-1 has insulin-sensitizing actions, but pre-
dominantly stimulates insulin release and also has
direct receptor-mediated action in heart and other
tissues. Oral dipeptidyl peptidase-4 inhibitors reduce
GLP-1 breakdown, thereby increasing endogenous
plasma GLP-1 levels. Only limited data exist on the
potential role of these drugs in CHF. A controlled
study investigated the impact of the dipeptidyl
peptidase-4 inhibitor saxagliptin on cardiovascular
outcomes in 16,492 type 2 diabetic patients at 2-year
follow-up. Saxagliptin did not reduce either the pri-
mary endpoint (cardiovascular death, nonfatal MI,
nonfatal ischemic stroke) or the secondary endpoint
(hospitalization for HF, coronary revascularization, or
unstable angina), but more patients in the saxagliptin
group were hospitalized for HF (105).
Sul fonylureas . Sulfonylureas inhibit the ATP-
sensitive potassium channel that is protective in
ischemia. However, a recent analysis of a large data-
base of patients presenting with acute coronary syn-
drome showed that diabetic patients had a greater
risk of death or HF within 30 days compared with
nondiabetic patients, although this risk was no higher
in diabetic patients treated with sulfonylureas prior
to admission (106).
MITOCHONDRIAL-TARGETED THERAPY TO IMPROVE
RESPIRATORY CHAIN FUNCTION. Mice overexpress-
ing mitochondrial catalase have a signiﬁcant life-
span extension and attenuated cardiac aging
(107,108). Mitochondrially-targeted peptides with
potent antioxidant effects were recently developed.
The Szeto-Schiller (SS31) peptide is a positively
charged free-radical scavenger that can accumulate
more than 1,000-fold in mitochondria (109). SS31
markedly ameliorated angiotensin II–induced car-
diomyopathy in a murine model; prevented cardiac
hypertrophy, ﬁbrosis, and diastolic dysfunction (110);
and improved mitochondrial function and skeletal
muscle performance in aged mice (111). In a murine
thoracic aortic constriction HF model, Dai et al. (112)
reported amelioration of LV systolic dysfunction
by SS31 treatment, associated with a reduction in
mitochondrial oxidative damage markers and asubstantial amelioration of proteomic changes
observed in cardiac muscle with HF development.
CoenzymeQ10 carries electrons from complex I to III
in the electron transport chain, and acts as an antiox-
idant. Plasma and cardiac tissue levels are reduced in
HF (113). There have been several studies of coenzyme
Q10 supplementation in HF, with variable results. A
meta-analysis showed an almost 4% improvement in
LV ejection fraction, but the beneﬁt was markedly
lower in patients taking standard therapies, including
angiotensin-converting enzyme inhibitors (114).
THERAPIES THAT MAY IMPROVE ENERGY TRANSFER.
As a consequence of ROS, especially derived from XO
and nicotinamide adenine dinucleotide phosphate
(NADPH) oxidase, myoﬁbrillar creatine kinase activity
is reduced. A recent nonrandomized study reported
that acute intravenous allopurinol increased creatine
kinase ﬂux in HF patients (115). Allopurinol reduces
oxidative stress by inhibiting XO. As discussed
earlier, a range of surrogate markers suggest a clinical
beneﬁt of XO inhibition as a tailored therapy option in
HF with hyperuricemia (116). In a large retrospective
study of 4,785 patients with HF and hyperuricemia, a
35% mortality reduction was observed with high-dose
allopurinol compared with low-dose allopurinol
therapy (117). A randomized controlled trial of oxy-
purinol (the active metabolite of allopurinol) in HF
patients, OPT-CHF (Oxypurinol Therapy for Conges-
tive Heart Failure), could not, however, conﬁrm a
clinical beneﬁt of this therapy (118).
Skeletal and cardiac muscle creatine content is
reduced inHF, largely due to reduced expression of the
creatine-sodium cotransporter (as discussed earlier).
In 1 study, intravenous creatine improved LV ejection
fraction (119). Although there is some evidence of
improved skeletal muscle function and exercise dura-
tionwith chronic oral carnitine administration, there is
no evidence of improved cardiac function (120).
OTHER THERAPIES WITH “METABOLIC” ACTION. HF
patients have low cardiac tissue carnitine levels
(121). Several carnitine supplementation studies in
HF reported variable results, warranting further
investigation (122). The testosterone deﬁcit has been
proposed as a novel therapeutic target in HF patients.
Testosterone replacement therapy was reported to
improve exercise capacity and symptomatic status in
men with CHF (123). Known cardiotoxic effects and
other side effects of anabolic steroids may hinder
wider acceptance of this therapeutic option.
Iron supplementation improved symptomatic sta-
tus patients with systolic HF and iron deﬁcit (61); this
was the ﬁrst successful implementation of a speciﬁc
metabolic treatment in HF (124).
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The complex interactions between metabolic, immu-
nologic, and neuroendocrine signals in HF are still
incompletely understood. Evidence is mounting that
the abnormal and imbalanced metabolism represents
an intrinsic aspect of HF pathophysiology, with
fundamental symptomatic and prognostic implica-
tions. The concept of metabolic failure in HF should
not be limited to impaired myocardial energy utili-
zation. Energy metabolism and structural metabolism
are as well affected on a systemic level. The HFmetabolic phenotype is characterized by insulin
resistance and global anabolic blunting and catabolic
overactivity. The increasing pathophysiologic under-
standing combined with novel ideas for targeted
metabolic treatments suggest that the metabolic facet
of HF may emerge as the next frontier in HF therapy.
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